- Home
- SOPH vs CLLS Comparison
SOPH vs CLLS Comparison
Compare SOPH & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOPH | CLLS |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | Switzerland | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.4M | 299.0M |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | SOPH | CLLS |
|---|---|---|
| Price | $4.81 | $4.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | ★ $8.00 |
| AVG Volume (30 Days) | 105.6K | ★ 147.2K |
| Earning Date | 11-04-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $73,297,000.00 | ★ $82,551,000.00 |
| Revenue This Year | $18.32 | $32.58 |
| Revenue Next Year | $15.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.66 | ★ 129.04 |
| 52 Week Low | $2.58 | $1.10 |
| 52 Week High | $5.30 | $5.48 |
Technical Indicators
Market Signals| Indicator | SOPH | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 55.20 | 42.87 |
| Support Level | $4.54 | $4.47 |
| Resistance Level | $4.84 | $5.45 |
| Average True Range (ATR) | 0.27 | 0.30 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 42.11 | 9.09 |
Price Performance
Historical ComparisonAbout SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.